ReviewClinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology2021
Type 2 immunity-driven diseases: Towards a multidisciplinary approach.
Review in Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 27 citations in OpenAlex.
- Case Report: Dupilumab combined with allergen-specific immunotherapy in severe atopic dermatitis and asthma.Frontiers in allergy · 2025Article
- Development and validation of a Delphi consensus-based questionnaire for the multidisciplinary management of type 2 inflammation-related diseases.Frontiers in allergy · 2025Article
- Skin Lipid Barrier: Structure, Function and Metabolism.Allergy, asthma & immunology research · 2024Review
- Role of Mast Cells in Eosinophilic Gastrointestinal Diseases.Immunology and allergy clinics of North America · 2024Review
- Cytokines in Allergic Conjunctivitis: Unraveling Their Pathophysiological Roles.Life (Basel, Switzerland) · 2024Review
- Race science without racists: how bigoted paradigms persist in allergy research.Frontiers in public health · 2024Article
- Multidisciplinary management of type 2 inflammation diseases using a screening tool.Frontiers in allergy · 2024Article
- Preclinical Development of SHR-1819, a Potent Humanized IL-4Rα Antibody for Treating Type 2 Inflammatory Diseases.Journal of inflammation research · 2024Article
- Combination of Biological Therapy in Severe Asthma: Where We Are?Journal of personalized medicine · 2023Review
- A Multidisciplinary Approach for Type 2 Allergic Diseases: What Do Biologics Teach Us?Journal of personalized medicine · 2023Article
- Addressing the unmet needs in patients with type 2 inflammatory diseases: when quality of life can make a difference.Frontiers in allergy · 2023Article
- White Paper on European Patient Needs and Suggestions on Chronic Type 2 Inflammation of Airways and Skin by EUFOREA.Frontiers in allergy · 2022Article
- In the Thick of It: Formation of the Tuberculous Granuloma and Its Effects on Host and Therapeutic Responses.Frontiers in immunology · 2022Review
- Type 2 immunity-driven diseases: Towards a multidisciplinary approach.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2021Review
- Quality of Life in Patients With Type 2 Inflammatory Asthma.Open respiratory archivesArticle
- Climate change and allergic diseases: A scoping review.The journal of climate change and healthReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 5 institutions in 1 country.
Funding
Abstract
Asthma, atopic dermatitis and chronic rhinoconjunctivitis are highly heterogeneous. However, epidemiologic associations exist between phenotypic groups of patients. Atopic march is one such association but is not the only common point. Indeed, beyond such phenotypes, hallmarks of type 2 immunity have been found in these diseases involving immune dysregulation as well as environmental triggers and epithelial dysfunction. From the canonical Th2 cytokines (IL-4, IL-5, IL-13), new cellular and molecular actors arise, from the epithelium's alarmins to new innate immune cells. Their interactions are now better understood across the different environmental barriers, and slight differences appeared. In parallel, the development of type 2-targeting biotherapies not only raised hope to treat those diseases but also raised new questions regarding their true pathophysiological involvement. Here, we review the place of type 2 immunity in the different phenotypes of asthma, chronic rhinitis, chronic rhinosinusitis and atopic dermatitis, highlighting nuances between them. New hypotheses rising from the use of biotherapies will be discussed along with the uncertainties and unmet needs of this field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.